Literature DB >> 28858296

CCN3 suppresses TGF-β1-induced extracellular matrix accumulation in human mesangial cells in vitro.

Hai-Fei Liu1, Hong Liu2, Lin-Li Lv2, Kun-Ling Ma2, Yi Wen2, Long Chen2,3, Bi-Cheng Liu2.   

Abstract

Glomerular sclerosis is characterized by mesangial cell proliferation and progressive extracellular matrix (ECM) accumulation. CCN3 belongs to the CCN family of matrix proteins; increasing evidence suggests that CCN3 is an endogenous negative regulator of the ECM and fibrosis. However, the exact role of CCN3 in the accumulation of ECM remains unknown. The aim of the present study was to investigate the effects of CCN3 on TGF-β1-induced production of ECM in human mesangial cells (HMCs) in vitro. Treatment with TGF-β1 (0.5-2.0 ng/mL) suppressed the mRNA and protein expression of CCN3 in HMCs in dose- and time-dependent manners. Furthermore, treatment with TGF-β1 significantly increased the expression of the two markers of renal fibrosis, fibronectin (FN) and type I collagen (COLI), in HMCs. Moreover, treatment with TGF-β1 significantly decreased the expression of metalloproteinase (MMP)-2 and MMP-9, and markedly increased the expression of tissue inhibitor of metalloproteinase (TIMP)-1 in HMCs. Pretreatment of HMCs with exogenous CCN3 (5-500 ng/mL) or overexpression of CCN3 significantly attenuated TGF-β1-induced changes in FN, COLI, MMP-2, MMP-9 and TIMP-1 in HMCs. These results suggest that CCN3 suppresses TGF-β1-induced accumulation of ECM in HMCs. CCN3 may have potential as a novel therapeutic target for alleviating glomerulosclerosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28858296      PMCID: PMC5800473          DOI: 10.1038/aps.2017.87

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  31 in total

Review 1.  NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues.

Authors:  B Perbal
Journal:  Mol Pathol       Date:  2001-04

2.  Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing.

Authors:  Cristiane G Lin; Chih-Chiun Chen; Shr-Jeng Leu; Tatiana M Grzeszkiewicz; Lester F Lau
Journal:  J Biol Chem       Date:  2004-12-20       Impact factor: 5.157

3.  Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.

Authors:  Wenzhao Li; Shigehira Saji; Fumiaki Sato; Makoto Noda; Masakazu Toi
Journal:  Int J Biol Markers       Date:  2013-06-28       Impact factor: 2.659

Review 4.  Matrix metalloproteinases (MMPs) in health and disease: an overview.

Authors:  Charles J Malemud
Journal:  Front Biosci       Date:  2006-05-01

5.  CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin-dependent pathway.

Authors:  Huey-En Tzeng; Jui-Ching Chen; Chun-Hao Tsai; Chien-Chung Kuo; Horng-Chaung Hsu; Wen-Lee Hwang; Yi-Chin Fong; Chih-Hsin Tang
Journal:  J Cell Physiol       Date:  2011-12       Impact factor: 6.384

6.  Effects of CCN3 on fibroblast proliferation, apoptosis and extracellular matrix production.

Authors:  Zhanping Ren; Yuxia Hou; Siwei Ma; Yongwei Tao; Jinfeng Li; Huiqin Cao; Lingling Ji
Journal:  Int J Mol Med       Date:  2014-04-08       Impact factor: 4.101

7.  Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring.

Authors:  A K Ahmed; J L Haylor; A M El Nahas; T S Johnson
Journal:  Kidney Int       Date:  2007-02-07       Impact factor: 10.612

8.  Urinary mRNA expression of CCN2/CCN3 as a noninvasive marker for monitoring glomerular structure changes in nondiabetic chronic kidney disease.

Authors:  Long Chen; Yong-Gui Wu; Dan Liu; Lin-Li Lv; Min Zheng; Hai-Feng Ni; Yu-Han Cao; Hong Liu; Pei Zhang; Jian-Dong Zhang; Bi-Cheng Liu
Journal:  Biomarkers       Date:  2012-10-15       Impact factor: 2.658

9.  Effect of bradykinin on renal mesangial cell proliferation and extracellular matrix secretion.

Authors:  C Y Liu; L L Zhou; Q Cheng; S N Jiang; J Sheng; J D Sun; J Y Zhao
Journal:  Genet Mol Res       Date:  2014-01-21

10.  Downregulation of CCN3 expression as a potential mechanism for melanoma progression.

Authors:  M Fukunaga-Kalabis; G Martinez; S M Telson; Z-J Liu; K Balint; I Juhasz; D E Elder; B Perbal; M Herlyn
Journal:  Oncogene       Date:  2007-10-29       Impact factor: 8.756

View more
  6 in total

1.  Higher Serum CCN3 Is Associated with Disease Activity and Inflammatory Markers in Rheumatoid Arthritis.

Authors:  Yingying Wei; Linan Peng; Yi Li; Na Zhang; Ke Shang; Lihua Duan; Jixin Zhong; Jie Chen
Journal:  J Immunol Res       Date:  2020-05-09       Impact factor: 4.818

2.  Evaluation of the inhibitory effect of tacrolimus combined with mycophenolate mofetil on mesangial cell proliferation based on the cell cycle.

Authors:  Yanfang Gao; Hui Yang; Yanhong Wang; Jihua Tian; Rongshan Li; Xiaoshuang Zhou
Journal:  Int J Mol Med       Date:  2020-08-07       Impact factor: 4.101

3.  Endothelial cells secreted endothelin-1 augments diabetic nephropathy via inducing extracellular matrix accumulation of mesangial cells in ETBR-/- mice.

Authors:  Hong-Hong Zou; Li Wang; Xiao-Xu Zheng; Gao-Si Xu; Yunfeng Shen
Journal:  Aging (Albany NY)       Date:  2019-03-29       Impact factor: 5.682

4.  PARP-1 and SIRT-1 are Interacted in Diabetic Nephropathy by Activating AMPK/PGC-1α Signaling Pathway.

Authors:  Hengmei Zhu; Zhi Fang; Jiehui Chen; Yun Yang; Jiacheng Gan; Liang Luo; Xiaojiang Zhan
Journal:  Diabetes Metab Syndr Obes       Date:  2021-01-25       Impact factor: 3.168

Review 5.  The Emerging Roles of CCN3 Protein in Immune-Related Diseases.

Authors:  Linan Peng; Yingying Wei; Yijia Shao; Yi Li; Na Liu; Lihua Duan
Journal:  Mediators Inflamm       Date:  2021-05-18       Impact factor: 4.711

6.  Astragaloside IV represses high glucose-induced mesangial cells activation by enhancing autophagy via SIRT1 deacetylation of NF-κB p65 subunit.

Authors:  Xiaolei Wang; Yanbin Gao; Nianxiu Tian; Zhiyao Zhu; Tao Wang; Jiayi Xu; Bingjie Wu; Nan Zhang
Journal:  Drug Des Devel Ther       Date:  2018-09-12       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.